Yeztugo® (lenacapavir) Injection

Covered: Yeztugo (lenacapavir) SC injection is authorized only for PrEP to reduce sexually acquired HIV‑1 in adults and adolescents weighing ≥35 kg (non‑PrEP uses are not covered). Key requirements: documented weight ≥35 kg and a negative HIV‑1 test ≤7 days before dosing, prescribed as part of a comprehensive HIV‑1 prevention strategy and by/with an HIV specialist, adherence to the dosing schedule (927 mg SC initial then 927 mg every 6 months ±2 weeks) with documentation of planned maintenance injections, and authorization limited to 7 months.

"Yeztugo is indicated for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in adults and adolescents weighing at least 35 kg who are at risk for HIV-1 acquisition."

Sign up to see full coverage criteria, indications, and limitations.